Scientific Intelligence

Stacey Aggarwal, PhD, is a pharmacologist and certified nutrition counselor whose work sits at the intersection of pharmaceutical-grade evidence standards and nutritional science.

Advanced training in pharmacology. The discipline is built around three questions that turn out to matter enormously in the food and supplement category and get asked far too rarely in it: How does dose influence effect of a compound? What happens when it meets another compound? And how much evidence does it take before a claim about either is worth believing?

Experience as a clinical oncology analyst. Stacey has worked over 6 years as a clinical oncology analyst – distilling information from complex clinical data, competitive landscapes, and regulatory environments into meaningful insights for pharmaceutical clients.

A certified nutrition counselor working directly with perinatal clients. What started as a passion project, client work now provides a unique perspective in this industry. Client conversations rarely touch on pharmaceuticals – they focus on food, botanicals, traditional practices, and supplements. These interactions inform my insights, colored by discussions with real women about dietary products and food during this transformative time.

Why the perinatal category is scientifically tricky

The perinatal category carries a set of problems that generalist review does not reliably catch:

Perinatal exposure is uniquely nuanced. Nearly every ingredient question becomes a placental transfer or milk transfer question. Absence of evidence in this population is routinely mistaken for evidence of safety.

A systematically thin evidence base. Pregnant and lactating people are excluded from most trials by design. The available literature is observational, extrapolated from non-pregnant populations, or absent entirely. This makes substantiation harder in this category, not easier - "there is a study" is rarely sufficient, and the FTC weighs the full body of evidence, not the citations a brand selects.

Botanicals have real pharmacology. Galactagogues, adaptogens, and traditional herbal blends carry documented receptor activity, CYP-mediated interactions, and adverse event literature. They are often formulated and marketed by teams with no pharmacology on staff.

A highly motivated, highly vulnerable buyer. This is precisely the population in which overclaiming is most profitable and most damaging, as well as and the one where enforcement attention and plaintiff interest concentrate.

Areas of work

Quarterly Intelligence Updates

Stay ahead of the science, regulatory landscape, and market.

A focused view of the developments shaping women’s health, perinatal nutrition, and dietary supplements to help teams spot risks, opportunities, and emerging trends before they become obvious.

Regulatory & policy developments.
Emerging science and industry trends
Market signals, competitive activity, and white space for innovation
Practical implications for your business

Product Analytics

See where products are moving and where opportunities remain.

Structured analysis of prenatal and women’s health products to reveal formulation trends, market gaps, competitive positioning, and areas for differentiation.

Formulation & nutrient trends
Competitive product comparisons
Market gaps and opportunities
Data-driven product insights

Custom Intelligence & Advisory

Answer the questions that matter most to your business.

Project-based research and scientific intelligence tailored to a specific product, market question, competitive landscape, or strategic decision.

Targeted market or competitive research
Scientific & product landscape analysis
Focused research questions
Strategic interpretation of complex information

Intelligence Partner Package

Build a fuller picture by connecting the dots.

The three offerings work independently, but together they provide an ongoing intelligence foundation: from what is changing, to what the market is doing, to what it means for your business.

Continuous visibility into a changing market
Proprietary data paired with broader market intelligence
Faster, more informed strategic decisions
Flexible access to deeper research when questions arise

How engagement begins

An introductory call, to understand the question, the timeline, what materials already exist, and share thoughts & capabilities.
A written scope and price, confirmed before any work starts. Rates are built around scope rather than published as a flat card.
Delivery in the format your team already works in, with a debrief call included on request.

What I don't do

I don't render legal conclusions. Whether evidence supports a claim is a scientific judgment. Whether a claim is deceptive or unlawful is a determination for counsel, and I stay on my side of that line.
I don't name specific products or companies in syndicated work unless the association is already independently public through a warning letter, recall, or filed litigation. Signal findings are reported at the ingredient and category level by design.
I don't guarantee regulatory or litigation outcomes. The work product is an evidentiary opinion current as of its review date, not a prediction of how a matter will resolve.
I don't work outside the perinatal window. General claims substantiation across unrelated categories is well served by larger firms built for that scope. This practice exists because that coverage reliably misses what is specific to pregnancy and lactation.

I am an independent scientific consultant. I don't lend my name to products, accept contingent compensation, or take engagements conditioned on reaching a particular conclusion. The full commitments are on my Ethics page.

Independent science. Clearer intelligence. Better decisions.